The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT02695810
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT02695810
-
- Other papers using this trial's data
- The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT02695810. Randomized; no masking; primary purpose prevention. Start 2016-02-24 (actual); primary completion 2018-09-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
- Condition
- Prediabetic State
- Condition
- Obesity
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Metformin
- Intervention (Behavioral)
- Exercise
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Collaborator
- The Novo Nordic Foundation
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- AstraZeneca
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02695810- Content hash
c677c743ba3bc3211825c332c5719d57399d0ec75bb0580a8bb10be581451183